TumorGenetics
What this study is
This study is a novel evaluation of cardiotoxicity after ICI therapy based on traditional CV risk factors with the addition of metabolomic profiles, epigenetic aging, and CHIP. It is not an extension of previous work in ICI therapy.
Study details
- Official title
- Metabolomic and Genetic Factors Decoupling Immune Checkpoint Inhibitor Tumor Efficacy and Cardiovascular Toxicity
- Sponsor
- M.D. Anderson Cancer Center
- Conditions
- Tumor · Cardiovascular
- Enrolling
- 1,200 people
- Starts
- 2026-01-09
- Est. completion
- 2030-06-30
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years and overSex ALLHealthy volunteers Not acceptedYou may qualify if
- Age ≥ 18 years
- Plan to start immune checkpoint inhibitor for cancer therapy
You can't join if
- No baseline blood collection prior to initiation
- At time of evaluation not determined to be a good candidate for evaluation of outcome events by the principal investigator
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
1
Study locations (1)
1 openThe University of Texas M. D. Anderson Cancer Center
Houston, Texas, United States
- Nicolas Palaskas, MD · Contact832-750-1109nlpalaskas@mdanderson.org
- Nicolas Palaskas, MD · Principal investigator
Recruiting
Study team
Sponsor
M.D. Anderson Cancer Center
Study ID 2025-1571
Principal investigator
Nicolas Palaskas, MD
M.D. Anderson Cancer Center
Have questions? The contacts above can answer them before you apply.
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.